Home >> MARKETPLACE >> Thermo Fisher offers plazomicin immunoassay

Thermo Fisher offers plazomicin immunoassay

Print Friendly, PDF & Email

February 2019—Thermo Fisher Scientific received FDA clearance for its de novo submission of its QMS Plazomicin Immunoassay. This quantitative immunoassay measures the concentration of a novel therapeutic antibiotic, plazomicin, using the Beckman Coulter AU 680 automated clinical chemistry analyzer. Plazomicin (Zemdri, Achaogen) is a next-generation aminoglycoside being used to treat patients with complicated urinary tract infections.

The QMS Plazomicin Immunoassay, developed in collaboration with Achaogen, is the latest addition to the company’s line of therapeutic drug monitoring immunoassays.

Thermo Fisher Scientific, 800-232-3342


Check Also

CMS extends coverage of Oncomine Dx test, 5/18

May 2018—Thermo Fisher Scientific announced its Oncomine Dx Target Test has been approved for coverage by the Centers for Medicare and Medicaid Services as part of the agency’s national coverage determination for next-generation sequencing in vitro diagnostic tests.